The University of Dundee’s Medical Research Council Protein Phosphorylation and Ubiquitylation (MRC PPU) unit has been awarded £27.4 million in additional funding from the Medical Research Council (MRC) to continue its groundbreaking research in cell signalling. This funding will support the unit’s ongoing work in developing reproducible reagents, allowing scientists to consistently replicate experiments and advance novel therapies.
Renowned for its contributions to the understanding and treatment of diseases such as Parkinson’s, immune disorders, and cancer, the MRC PPU has been instrumental in the discovery of new drugs. Its long-running collaboration with industry, the Division of Signal Transduction Therapy (DSTT), has attracted £60 million in investment since its inception, leading to over 40 cancer-targeting drugs being approved for clinical use.
Unit director Dario Alessi emphasized the importance of this renewed funding, stating that it will allow the MRC PPU to continue its partnerships with pharmaceutical companies and accelerate drug discovery. MRC executive chair Professor Patrick Chinnery praised the unit’s leadership in translating rigorous fundamental research into patient-focused breakthroughs, highlighting its collaborative culture.
Read the full story here.
